Skip to main content
SpringerLink
Log in

Sarcoidosis and the heart

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

  • The treatment of sarcoid cardiomyopathy can be considered in part the treatment of the systemic disorder, and in part cardiac involvement, the manifestations of which may differ greatly. Therapy for the systemic disease is corticosteroid. Therapy for cardiac involvement includes prednisone, but because treatment must ameliorate or abolish many differing manifestations, therapy differs among patients.

  • Asymptomatic patients (the majority) who are free from serious manifestations of the disease do not require pharmacologic or interventional treatment.

  • Patients with dilated cardiomyopathy require treatment for congestive heart failure.

  • High-grade atrioventricular conduction delay usually necessitates a permanent electronic pacemaker.

  • Life-threatening arrhythmia usually requires implantation of an automatic implantable cardiac defibrillator (AICD). Antiarrhythmic drugs may also be needed.

  • Cardiac tamponade should be treated by drainage of pericardial fluid.

  • Pericardiectomy is usually the appropriate treatment for patients who develop significant constrictive pericarditis.

  • Calcium channel blockers may be helpful for severe diastolic dysfunction that occurs in those with restrictive cardiomyopathy.

  • Therapy should be given to those few patients who manifest hypertrophic cardiomyopathy to relieve left ventricular outflow obstruction.

  • Cardiac transplantation for intractable heart failure or arrhythmia may be needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Crystal RG: Pulmonary sarcoidosis, a disease characterized by and activated by lung T lymphocytes. Ann Int Med 1981, 94:73–94.

    Google Scholar 

  2. Yasaki Y, Isobar M, Hermits S, et al.: Comparison of clinical features and prognosis of cardiac sarcoidosis. Am J Cardiol 1998, 82: 537–540.

    Article  Google Scholar 

  3. Shamas RL, Movahed A: Successful treatment of myocardial sarcoidosis with steroids. Sarcoidosis 1994, 11:37–39. Excellent account of the use of steroid therapy for sarcoid heart disease.

    Google Scholar 

  4. Probert CS, Pavord I, Roland J: Steroid responsive cardiomyopathy. Int J Cardiol 1990, 28:257–258.

    Article  PubMed  CAS  Google Scholar 

  5. Cooper LT Jr., Berry GJ, Shabetai R: Idiopathic giant-cell myocarditis—natural history and treatment. N Engl J Med 1997, 336:1860–1866.

    Article  PubMed  Google Scholar 

  6. Litovski SH, Burke AP, Virmani R: Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996, 9:1126–1134. Giant cell myocarditis is often confused with cardiac sarcoidosis. The correct distinction is important, because therapy for giant cell myocarditis has to be much more intense.

    Google Scholar 

  7. Davidoff R, Palacios I, Southern J, et al.: Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long term outlook. Circulation 1991, 83:953–961.

    PubMed  CAS  Google Scholar 

  8. Miller LW: Idiopathic dilated cardiomyopathy. Curr Treat Option Cardiovasc Med 2000, 2:421–430.

    Google Scholar 

  9. The RALES investigators: Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am J Cardiol 1996, 78:902–907.

    Article  Google Scholar 

  10. Digitalis Investigation Group: The effects of digoxin on mortality and morbidity in patients with heart failure. N Eng J Med 1997, 336:524–533.

    Article  Google Scholar 

  11. The SOLVD investigators: The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991, 35:283–302.

    Google Scholar 

  12. Pitt B, Segal R, Martinez FA, et al.: Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997, 349:747–752.

    Article  PubMed  CAS  Google Scholar 

  13. Cleland JGF, Bulpitt CJ, Falk RH: Is aspirin safe for patients with heart failure? Br Heart J 1995, 74:524–533.

    Google Scholar 

  14. Bristow MR, Gilbert EM, Abraham WT, for the MOHA investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in patients with chronic heart failure. Circulation 1996, 94:2807–2816.

    PubMed  CAS  Google Scholar 

  15. Bristow MR: Mechanisms of action of beta blocking agents in heart failure. Am J Cardiol 1997, 80(suppl L):26L-40L.

    Article  PubMed  CAS  Google Scholar 

  16. Kushwaha SS, Fallon JT, Fuster V: Restrictive cardiomyopathy. N Eng J Med 1997, 336:267–276. Although restrictive cardiomyopathy is less common than dilated in sarcoid heart disease, this authoritative review will be valuable to physicians who encounter a case of sarcoid restrictive cardiomyopathy.

    Article  CAS  Google Scholar 

  17. Winters SL, Cohen M, Greenberg S, et al.: Sustained ventricular tachycardia associated with sarcoidosis: assessment of the cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991, 18:937–943.

    Article  PubMed  CAS  Google Scholar 

  18. Paz HL, McCormick SP, Patchefsky A: The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis. Chest 1994, 106:603–607.

    Google Scholar 

  19. Roberts WC, McAllister HA, Farrans VJ: Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described patients (group 11). Am J Med 1977, 63:101–108. This is not a recent publication, but remains as one of the outstanding descriptions of cardiac sarcoidosis.

    Article  Google Scholar 

  20. Valentine HA, Tazlelaar HD, Macoviak J: Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant 1987, 6:244–250.

    Google Scholar 

  21. Oni AA, Hershberger RE, Norman DJ: Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 1992, 11:367–369.

    PubMed  CAS  Google Scholar 

  22. Yazaki Y, Isobe M, Hayasaka M, et al.: Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J 1998, 62:465–468.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology 111A, Veterans Affairs Health Care System, 3350 La Jolla Village Drive, 92161, La Jolla, CA, USA

    Ralph Shabetai MD

Authors
  1. Ralph Shabetai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shabetai, R. Sarcoidosis and the heart. Curr Treat Options Cardio Med 2, 385–397 (2000). https://doi.org/10.1007/s11936-000-0034-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-000-0034-x

Keywords

Search

Navigation